PSMA4 gene variations affect the efficacy and toxicity of proteasome inhibitors like bortezomib and carfilzomib, used in cancer therapy, by altering the degradation process of these drugs. Additionally, PSMA4 influences the metabolism or clearance of cotinine, indicating possible impacts on how nicotine and its byproducts are processed in the body.